ClinConnect ClinConnect Logo
Search / Trial NCT06953609

Prediabetes and Type 2 Diabetes in Aging

Launched by UŞAK UNIVERSITY · Apr 29, 2025

Trial Information

Current as of November 10, 2025

Enrolling by invitation

Keywords

Type 2 Diabetes Mellitus Cognitive Function Dual Task Fatigue Prediabetes

ClinConnect Summary

This study will look at how prediabetes and type 2 diabetes in older adults relate to thinking skills, sense of direction, reaction time, physical function, and fatigue. It compares four groups: healthy older adults with normal blood sugar, those with prediabetes, those with type 2 diabetes that is fairly well controlled, and those with type 2 diabetes that is less well controlled. They will assess cognitive status using a brief thinking test (MoCA), along with several other tests of memory, coordination, and fatigue.

About 80 people aged 60 and older will take part at four clinics in Uşak, Turkey. At enrollment, participants will undergo a series of tests and blood tests, including a cognitive screening (MoCA), sense-of-direction questionnaire, reaction time test, blood sugar, morning cortisol, dual-task walking tests, a short walking test, fatigue questionnaires, and blood work (hemoglobin, ferritin, TSH, CRP). This is an observational study, meaning no treatment is given by the study, and personal data won’t be shared publicly. The study is led by Uşak University (principal investigator Kevser Gürsan).

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • for people without diabetes (healthy), those with Hemoglobin A1c Levels (HbA1c) normal range between 4% and 5.6%,
  • those with HbA1c level between 5.7% and 6.4%, those with prediabetes (Impaired Glucose Tolerance),
  • those with 6.5% -7.5% level and
  • those with HbA1c level above 7.5
  • criteria are being 60 years of age and older,
  • Exclusion Criteria:
  • those who have major depression,
  • uncontrolled thyroid disease,
  • those with vitamin B12, folic acid deficiency and anemia,
  • those with uncontrolled hypertension,
  • those with nephropathy and retrophy,
  • those with any neuropsychological disorder, a history of alcohol, substance or drug addiction,
  • those using any neurological or psychological medication (anticonvulsant drugs, antidepressants, anxiolytics, etc.),
  • those with Alzheimer's and Parkinson's disease,
  • those with cancer,
  • those with lung disease

About Uşak University

Uşak University is a distinguished academic institution dedicated to advancing research and education in various fields, including the health sciences. As a clinical trial sponsor, Uşak University is committed to fostering innovation and contributing to medical knowledge through rigorous scientific investigation. The university collaborates with healthcare professionals and researchers to conduct high-quality clinical trials that aim to improve patient outcomes and enhance therapeutic interventions. With a focus on ethical standards and regulatory compliance, Uşak University strives to ensure the integrity and reliability of its research initiatives, ultimately benefiting the broader community and the advancement of healthcare practices.

Locations

Usak, Turkey

Patients applied

0 patients applied

Trial Officials

Kevser Gursan, Dr.

Principal Investigator

Uşak University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported